Id
18793
18794
Deadline Date
28/04/2017
Date Submitted
24/04/2017
Type
Performance in Delivering
NHS provider
Norfolk and Norwich University Hospitals NHS Foundation Trust
Research Ethics
Committee Reference
Number
13/NE/0330
14/SW/1029
Integrated Research
Application System
Number
Name of Trial
Target Number Of Minimum Number Of Patients
Patients Agreed? Agreed (Enter Same In Both If
Only One Number)
Number Agreed
5
5 Date Agreed
31/07/2015
5
18/05/2016
5 Recruitment Finished
155144
A Multicenter, Randomized, Double Blind, Placebo Controlled
Study to Assess the Long-Term Efficacy and Safety of
Prolonged Release Fampridine (BIIB041) 10 mg, Administered
Twice Daily in Subjects with Multiple Sclerosis (ENHANCE).
Number Agreed
6
6 Date Agreed
30/11/2015
8
18/05/2016
8 Recruitment Finished
Number Agreed
2
2 Date Agreed
30/06/2015
2
17/05/2016
2 Recruitment Finished
Number Agreed
5
5 Date Agreed
31/08/2016
7
31/08/2016
7 Recruitment Finished
Number Agreed
14
14 Date Agreed
28/02/2016
14
20/07/2016
14 Recruitment Finished
Number Agreed
3
3 Date Agreed
14/07/2016
4
14/07/2016
4 Recruitment Finished
Number Agreed
5
5 Date Agreed
03/08/2016
2
03/08/2016
2 Recruitment Finished
Number Agreed
3
3 Date Agreed
20/09/2016
2
20/09/2016
2 Recruitment Finished
127017
18796
13/EE/0312
137139
18797
15/WM/0238
182784
18798
13/YH/0201
129722
18799
15/ES/0115
183031
18800
15/SC/0583
187388
An International Phase 3 Randomized Trial of Autologous
Dendritic Cell Immunotherapy (AGS-003) Plus Standard
Treatment of Advanced Renal Cell Carcinoma
Efficacy and Safety of AM-101 in the Treatment of Acute
Peripheral Tinnitus 3 (TACTT3)
Investigation of safety and efficacy of once daily semaglutide
in obese subjects without diabetes mellitus. A 52 week,
randomised, double-blind, placebo-controlled, nine-armed,
parallel group, multi centre, multi-national trial with
liraglutide 3.0 m
The efficacy, safety and tolerability of Sativex as an adjunctive
treatment to existing anti-spasticity medications in children
aged 8 to 18 years with spasticity due to cerebral palsy or
traumatic central nervous system injury who have not
responded
Open Label, Multinational, Multicenter, Real World
Treatment Study of Single Agent AZD9291 for Patients with
Advanced/Metastatic Epidermal Growth Factor Receptor
(EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer
(NSCLC) Who Have Received Prio
A Phase 2, Double-blind, Randomized, Placebo-Controlled,
Multicenter Study Evaluating the Safety and Efficacy of GS5745 in Subjects with Moderately to Severely Active Crohn?s
Disease
18801
15/SC/0580
184910
18802
15/EE/0464
183877
A Combined Phase 2/3, Double-Blind, Randomized, PlaceboControlled, Induction and Maintenance Study Evaluating the
Safety and Efficacy of GS-5745 in Subjects with Moderately to
Severely Active Ulcerative Colitis.
Number Agreed
A Phase 3, Placebo-Controlled, Randomized, Double-Blind,
Multi- Center Study of LJPC-501 in Patients with
Catecholamine-Resistant Hypotension (CRH)
Number Agreed
20064
15/EE/0391
189145
20066
11/AL/0167
Reason For Closure Of Trial
106121
13/LO/0733
15/LO/1236
Target Date To Recruit Date Agreed to recruit Total Number Of Patients
Date That The Trial Total Number Of Study
Patients Agreed?
target number of patients Recruited At The Agreed Closed To Recruitment Participants Recruited
Target Date
A pilot study to determine the safety and efficacy of
autologous adipose tissue banking in breast reconstruction
following cancer
18795
20065
Maximum Number Of Patients
Agreed (Enter Same In Both If Only
One Number)
4
4 Date Agreed
28/02/2018
0
21/09/2016
0 Withdrawn By Sponsor
3
3 Date Agreed
30/09/2016
0
01/12/2016
0 Recruitment Finished
Golimumab: A UK Two-part Observational Study Of Its
Utilisation And Impact in Patients with Ankylosing Spondylitis Number Agreed
9
9 Date Agreed
17/10/2016
9
17/10/2016
9 Recruitment Finished
183416
A Phase 3, Randomized, Multi-center, Double-Blind, PlaceboControlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus
Standard of Care vs. Placebo Plus Standard of Care in Subjects
with Light Chain (AL) Amyloidosis
Number Agreed
4
4 Date Agreed
04/01/2020
0
16/01/2017
0 Withdrawn By Sponsor
69703
Clinical investigation of a DES (Mistent system) with Sirolimus
and a bioabsorbable polymer for the treatment of patients
with De Novo lesions in native coronary arteries.
Number Agreed
2
2 Date Agreed
06/01/2017
2
20/01/2017
2 Recruitment Finished
Comments
Study closed early by Sponsor due to lack of
recruitment. Recruitment was expected to be
slow/low because the entry criteria required
failure of all standard therapies.
Study clsoed early locally by the Sponsor